A Phase 1/2 interventional study of IIV-HD and rC19 (dose 1) in COVID-19 Immunization and Influenza Immunization, sponsored by Sanofi. Completed at 12 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Sanofi · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Influenza, Human by Sanofi — 4 open to participants now, 6 under way, 1 of them phase 3. Influenza, Human · Sanofi.
Among the 139 studies in Influenza, Human by Sanofi, this one is the 28th largest by enrollment of the 126 interventional ones that give a count, is one of 8 that started in 2024, is one of 13 in phase 1/2, and was the 127th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →4 of the 139 studies in Influenza, Human by Sanofi are open now, in 3 countries. Recruiting first, the newest first:
Sanofi · Sites in Poland
Ages 60+ · Healthy volunteers
Sanofi · Sites in Korea, Republic of
Ages 65+ · Healthy volunteers
Sanofi · Sites in United States
Ages 18+ · Healthy volunteers
Sanofi · Sites in Korea, Republic of
Ages 65+ · Healthy volunteers
By country, each count listing its studies:
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 47 · Phase 3 35 · Phase 4 33
First in 2003; this study’s year is marked. 8 started in 2024.
This study's enrollment of 980 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 305 across the 126 interventional studies, 1,001 across the 13 observational. Of the 133 that completed or were terminated, 73 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
2 of the studies in Influenza, Human by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06907511SanofiStudy to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older | 2026-12-01 |
| NCT07516418SanofiStudy of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age | 2027-04-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 139 studies in Influenza, Human by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States.
The purpose of the study is to assess the safety and immunogenicity of IIV-HD (high-dose inactivated influenza vaccine) + rC19 (adjuvanted recombinant COVID-19 vaccine) vaccine comprised of IIV-HD combined with different recombinant Spike (rS) antigen levels of rC19 compared to IIV-HD alone, rC19 (dose 1) alone, and IIV-HD and rC19 (dose 1) (coadministered in opposite arms).
Placebo will be coadministered in the IIV-HD alone, rC19 (dose 1) alone, and IIV-HD + rC19 study groups to control for the number of injections and to maintain observer-blinding.
Thus, each participant will receive two injections at enrollment, one in each deltoid muscle.
Study details include:
Number of Participants:
Approximately 980 participants are expected to be randomized.
Inclusion Criteria:
Inclusion criteria to be checked at Screening Visit
Inclusion criteria to be checked at Visit 1 (D01):
A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
OR
A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) on the day of enrollment before the first dose of study intervention.
Exclusion Criteria:
Exclusion criteria to be checked at Screening Visit and at Visit 1 (D01):
Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
two IM injections on D01
Biological: IIV-HD · Other: Placebo (0.9% NaCl)
two IM injections on D01
Biological: rC19 (dose 1) · Other: Placebo (0.9% NaCl)
two IM injections on D01
Biological: IIV-HD · Biological: rC19 (dose 1)
two IM injections on D01
Biological: IIV-HD + rC19 (dose 1) · Other: Placebo (0.9% NaCl)
two IM injections on D01
Biological: IIV-HD + rC19 (dose 2) · Other: Placebo (0.9% NaCl)
two IM injections on D01
Biological: IIV-HD + rC19 (dose 3) · Other: Placebo (0.9% NaCl)
two IM injections on D01
Biological: IIV-HD + rC19 (dose 4) · Other: Placebo (0.9% NaCl)
Inactivated, split-virion
Protein subunit
IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
Normal saline
Number of participants with immediate adverse events (AEs)
Immediate adverse events are any unsolicited systemic adverse events reported in the 30 minutes after vaccination
Time frame: Within 30 minutes after each vaccination
Number of participants with solicited injection site reactions
Solicited injection site reactions include injection site pain, erythema and swelling
Time frame: Up to 7 each days after vaccination
Number of participants with solicited systemic reactions
Solicited systemic reactions include fever, headache, fatigue, myalgia and chills
Time frame: Up to 7 days after each vaccination
Number of participants with unsolicited AEs
Unsolicited (spontaneously reported) AEs, not fulfilling criteria for solicited adverse reactions
Time frame: Up to 28 days after each vaccination
Number of participants with adverse events of special interest (AESIs)
AESIs
Time frame: Up to 180 days after each vaccination
Number of participants with medical attended adverse events (MAAEs)
MAAEs
Time frame: Up to 180 days after each vaccination
Number of MAAEs relating to predefined potential immune-mediated disease (PIMDs)
MAAEs relating to predefined PIMDs
Time frame: From D182 through 12 months following the last study vaccination
Number of participants with serious adverse events (SAEs)
SAEs
Time frame: Up to 180 days after each vaccination
Number of participants with related SAEs
Related SAEs
Time frame: From D182 through 12 months following the last study vaccination
Number of MAAEs relating to predefined PIMDs that meet the criteria for SAEs
MAAEs relating to predefined PIMDs that meet the criteria for SAEs
Time frame: From D182 through 12 months following the last study vaccination
Geometric mean (GM) of HAI titers in all participants
HAI titers
Time frame: At D01 and D30
Geometric mean ratio (GMR) HAI titers ratio D30/D01 in all participants
Individual HAI titers ratio D30/D01
Time frame: At D01 and D30
GM of SARS-CoV-2 neutralizing titers in all participants
SARS-CoV-2 neutralizing titers
Time frame: At D01 and D30
GMR of SARS-CoV-2 neutralizing titers ratio D30/D01 in all participants
Individual SARS-CoV-2 neutralizing titers ratio D30/D01
Time frame: At D01 and D30
Percentage of participants with seroconversion in all participants
Seroconversion is defined by: HAI titer \< 10 \[1/dil\] at D01 and post-injection titer ≥ 40 \[1/dil\] at D30 or HAI titer ≥ 10 \[1/dil\] and a ≥ 4-fold increase in titer \[1/dil\] at D30
Time frame: At D30
Percentage of participants with HAI titer ≥ 10 (1/dil) in all participants
detectable HAI titer ≥ 10 (1/dil)
Time frame: At D01 and D30
Percentage of participants with HAI titer ≥ 40 (1/dil) in all participants
HAI titer ≥ 40 (1/dil)
Time frame: At D01 and D30
Percentage of participants with seroresponse to SARS-CoV-2 in all participants
Seroresponse to SARS-CoV-2 is defined by SARS-CoV-2 neutralizing titers ≥ 4-fold rise in SARS-CoV-2 neutralizing titers from D01 to D30
Time frame: At D30
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Nov 2024 to primary completion in Apr 2026, 16 months.
Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 16 months is above that.
Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.